Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
Open Access
- 27 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-12
- https://doi.org/10.1038/s41598-021-82068-9
Abstract
Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib. Peripheral blood from 30 NSCLC patients before, after 1 cycle of osimertinib and at progression of disease (PD) was analyzed by size-based CTC enrichment combined with RT-qPCR for gene expression of epithelial (CK-8, CK-18, CK-19), mesenchymal/EMT (VIM, TWIST-1, AXL), stem cell (ALDH-1) markers, PD-L1 and PIM-1. CTCs were also analyzed by triple immunofluorescence for 45 identical blood samples. Epithelial and stem cell profile (p = 0.043) and mesenchymal/EMT and stem cell profile (p = 0.014) at PD were correlated. There was a strong positive correlation of VIM expression with PIM-1 expression at baseline and increased PD-L1 expression levels at PD. AXL overexpression varied among patients and high levels of PIM-1 transcripts were detected. PD-L1 expression was significantly increased at PD compared to baseline (p = 0.016). The high prevalence of VIM positive CTCs suggest a dynamic role of EMT during osimertinib treatment, while increased expression of PD-L1 at PD suggests a theoretical background for immunotherapy in EGFR-mutant NSCLC patients that develop resistance to osimertinib. This observation merits to be further evaluated in a prospective immunotherapy trial.Funding Information
- Stavros Niarchos Foundation (16785)
This publication has 67 references indexed in Scilit:
- A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialClinical Cancer Research, 2016
- Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe DiseaseScientific Reports, 2016
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor NivolumabScientific Reports, 2016
- Characterization of different CTC subpopulations in non-small cell lung cancerScientific Reports, 2016
- Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case studyAnnals of Oncology, 2016
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersClinical Cancer Research, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent ApproachesJournal of Thoracic Oncology, 2012
- A highly specific real‐time RT‐PCR method for the quantitative determination of CK‐19 mRNA positive cells in peripheral blood of patients with operable breast cancerInternational Journal of Cancer, 2006